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Available online xxxThe paradigm of antiretroviral therapy shifted in the last few
years from the “mantra” of triple therapy to the possibility of using
two-drug combination initially as maintenance strategies [1], and in
fact as first-line regimens [2]. The possibility of such a shift was
allowed by the availability of compounds with a high genetic barrier
to resistance as “core agents”, protease inhibitors, and the second-
generation integrase inhibitor dolutegravir. This strategy looks at
the avoidance of untoward long-term effects related to the expo-
sure of antiretrovirals with regards to nucleos(t)ide reverse tran-
scriptase inhibitors with potential metabolic [3], bone and renal
toxicities [4]. Nevertheless, for a relevant percentage of patients,
the possibility to switch to regimens composed of fewer drugs is
challenged by the presence of archived genotypic mutations in
their historical genotype.
In the recent article published in EBioMedicine, De Miguel and co-
workers assessed the switch to dolutegravir plus lamivudine in
patients without previous exposure to integrase inhibitors with and
without previously acquired lamivudine resistance [5]. The study
addresses a topic that continues to challenge physicians involved in
the treatment of people living with HIV. In particular, the possibility
of switching patients with a lamivudine containing dual regimen
with and without previously archived lamivudine resistance in the
historical RNA genotype. The authors selected only patients without
a lamivudine resistance detectable at the time of the switch in the
proviral DNA by Sanger sequencing. The authors concluded that dolu-
tegravir plus lamivudine was effective in maintaining virological sup-
pression despite the presence of lamivudine resistance mutations inDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2020.102779.
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assessed by next-generation sequencing.
Some limitations related to the pilot-study design warrant a men-
tion. First, the small study population warrants us to interpret the
findings with caution. The probability of virological failure at 48
weeks, which was the primary and endpoint is not a frequent event
in patients who switch under virological control. The limited sample
size may have influenced the results toward showing no difference
between the groups. Second, the convenience sample from patients
enrolled in a previous study (GEN-PRO [6]) could have introduced a
selection bias by enrolling patients with a good adherence to antire-
trovirals and with higher probability of treatment success. Third, the
use of proviral DNA to guide clinical decision to change an antiretro-
viral regimen could be questionable. This strategy may not be feasible
for the majority of clinical centers that manage people living with HIV
including some high income countries, especially when we consider
the use of next-generation sequencing. On one hand, the assumption
that a negative detection of resistance at the time of the switch in the
proviral DNA correlate with the time of viral suppression before the
switch may sound reasonable, but on the other side, it may be ques-
tionable due to the possible presence of archived mutations not
detected by the test or the fading away of latently infected cells.
Nonetheless, the increased sensitivity provided by a next-generation
sequencing facilitates more informed decision making to make the
therapeutic switch is still a matter of debate. The findings of the pres-
ent study confirm that there is no difference in virological failure in
those with and without lamivudine resistance detected by next-gen-
eration sequencing [7].
Data from observational studies suggest that the time of viral sup-
pression before the switch in patients under virological control with
previous NRTIs resistance could be one of the most important factors
in determining the risk of virological failure [8]. The study by De
Miguel et al. underlines that patients with previous lamivudine resis-
tance had a longer duration of viral suppression before the switch
compared to those without lamivudine resistance (7.7 years vs 5.3
years) [5]. Thus, the prolonged viral suppression in patients with
archived lamivudine resistance could have increased the probability
of virological success when compared to those without resistance.
We also have to consider the growing evidence that NRTIs can
contribute to treatment success in the presence of previous resis-
tance, in the reverse transcriptase or other enzymes, when combined
with a high-genetic-barrier anchor drug. While this effect could beder the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
2 A. Giacomelli et al. / EBioMedicine 56 (2020) 102820class- or drug-specific, M184V/I data suggest that the duration of
virological suppression has a critical role in decreasing the amount of
previously resistant variants below a clinically relevant threshold.
Although these findings are preliminary, after combining them
with those coming from observational studies [9, 10] we can suggest
the possibility to simplify patients who have archived in their histori-
cal genotype lamivudine resistance to dolutegravir plus lamivudine
as a maintenance regimen.
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